Effects of Hochuekkito on Lenvatinib-Induced Fatigue in Mice-Reference-Cited by-同舟云学术

Effects of Hochuekkito on Lenvatinib-Induced Fatigue in Mice

Published:2023 Issue:1 Volume:6 Page:1-7
ISSN:2434-432X
Container-title:BPB Reports
language:en
Short-container-title:

Author:

Xu Jinyang¹,Nakamura Ikuo¹,Sudo Makoto¹,Noda Satoshi²,Fujitsuka Naoki³,Mogami Sachiko³,Mitani Keiko¹,Tada Masaharu¹,Fujimoto Yasuhiro¹,Terada Tomohiro⁴,Hirono Seiko¹,Hatano Etsuro⁵

Affiliation:

1. Department of Gastroenterological Surgery, Hyogo Medical University, Hyogo, Japan

2. Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan

3. Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan

4. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan

5. Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Publisher

Pharmaceutical Society of Japan

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/bpbreports/6/1/6_1/_pdf

Reference52 articles.

1. 1) Wiegering A, Korb D, Thalheimer A, Kämmerer U, Allmanritter J, Matthes N, Linnebacher M, Schlegel N, Klein I, Ergün S, Germer CT, Otto C. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. Neoplasia, 16, 972–981 (2014).

2. 2) Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs, 79, 665–674 (2019).

3. 3) Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim. Biophys. Acta Rev. Cancer, 1874, 188391 (2020).

4. 4) Bruheim S, Kristian A, Uenaka T, Suo Z, Tsuruoka A, Nesland JM, Fodstad Ø. Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int. J. Cancer, 129, 742–750 (2011).

5. 5) Hao Z, Wang P. Lenvatinib in Management of Solid Tumors. Oncologist, 25, e302–e310 (2020).